Back to results
US 2022/0034903 A1Published application
Therapies That Target Autoimmunity For Treating Glaucoma And Optic Neuropathy
AssigneesThe Schepens Eye Research Institute, Inc., Massachusetts Institute of Technology
InventorsDong Feng Chen, Jianzhu Chen, Huihui Chen
Life of this patent
Estimating the term…
Abstract
The present invention comprises a composition with means to inhibit an autoimmune response and methods for using this composition to treat glaucoma and optic neuropathy.
Claims28
A method for inhibiting or reducing the severity of retinal ganglion cell (RGC) damage or axonal damage in a subject comprising
- locally administering to an ocular or adnexal tissue of said subject a composition comprising an immunosuppressant agent,
- thereby inhibiting or reducing the severity of said RGC damage or axonal damage,
- wherein said subject comprises an elevated level of heat shock protein 27 (hsp27)- or heat shock protein 60
- (hsp60)-reactive CD4+ T cells in peripheral blood, whole blood, vitreous humor, or aqueous humor compared to the level of said T cells of an age-matched healthy control;
- and
- wherein said agent inhibits autoreactive CD4+ T cells.
3 more elements
Dependencies are inferred from the claim text.